Clinical trials
catalyst calendar across sponsors →Studies where OBIO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 5 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC) · FINRA short interest 13.4 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Virtue® SAB in the Treatment of Coronary ISR TrialNCT07045194Target Lesion Failure (TLF) at 12 monthsRandomized · Single-masked · Treatment | Not applicable | Recruiting | Device: Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon | Coronary Artery Disease | 740 | Oct 2028 | ≤ 804 d | 2026-07-23 |
| BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638Change from Baseline in the Mean 24-hour ambulatory systolic blood pressure (aSBP) at 3 MonthsRandomized · Triple-masked · Treatment | Not applicable | Recruiting | Device: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated | Hypertension, Hypertension, Systolic, Hypertension, Essential | 500 | Dec 2026 | ≤ 134 d | 2026-07-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19